Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma

Journal of Hepatology

Volumn 57, Issue 1, 2012, Pages 101-107

  Personeni, Nicola ^a   Bozzarelli, Silvia ^a   Pressiani, Tiziana ^a   Rimassa, Lorenza ^a   Tronconi, Maria Chiara ^a   Sclafani, Francesco ^a   Carnaghi, Carlo ^a   Pedicini, Vittorio ^a   Giordano, Laura ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

AFP response; Alpha fetoprotein; Hepatocellular carcinoma; Landmark analysis; RECIST; Sorafenib; Survival

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; BILIRUBIN; SORAFENIB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOLISM; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE CONTROL; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DRUG MONITORING; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84862640821     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.02.016     Document Type: Article

References (27)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
3. Therasse P. Measuring the clinical response: what does it mean? Eur J Cancer 2002;38:1817-1823.
4. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-4300.
5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
6. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006;101:524-532.
7. Chen CH, Huang GT, Yang PM, Chen PJ, Lai MY, Chen DS, et al. Hepatitis Band C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur J Cancer 2006;42:2524-2529.
8. Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001;34 (4):603-605.
9. Chen LT, Liu TW, Chao Y, Shiah HS, Chang JY, Juang SH, et al. Alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. Aliment Pharmacol Ther 2005;22:217-226.
10. Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009;27:446-452.
11. Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 2009;14:717-725.
12. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL, et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010;116:4590-4596.
13. Pressiani T, Rimassa L, Boni C, Labianca R, Fagiuoli S, Ardizzoni A, et al. Phase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment. J Clin Oncol 2011;29 (abstr 4115).
14. A new prognostic system for hepatocellular carcinoma. A retrospective study of 435 patients - The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-755.
15. Chen LT, Shiah HS, Chao Y, Chang JY, Cheng LT, Whang-Peng J. Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent. J Clin Oncol 2009;27:e271.
16. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-719.
17. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomized controlled trial. Lancet Oncol 2008;9:132-138.
18. Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009;27:5734-5742.
19. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989;64:1700-1707.
20. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996;77:2217-2222.
21. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
22. Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2011. http://dx.doi.org/10.1002/cncr.26255, [Epub ahead of print].
23. Weiss GB, Bunce III H, Hokanson JA. Comparing survival of responders and non-responders after treatment: a potential source of confusion in interpreting cancer clinical trials. Control Clin Trials 1983;4:43-52.
24. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 2008;26:3913-3915.
25. Horger M, Lauer UM, Schraml C, Berg CP, Koppenhöfer U, Claussen CD, et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 2009;9:208.
26. Faivre S, Zappa M, Vilgrain V, Boucher E, Douillard JY, Lim HY, et al. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clin Cancer Res 2011;17:4504-4512.
27. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Panel of experts in HCC-design clinical trials. Design and end points of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.